We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Apellis Pharmaceuticals Inc (APLS) USD0.0001

Sell:$32.95 Buy:$32.96 Change: $0.58 (1.74%)
NASDAQ:0.05%
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$32.95
Buy:$32.96
Change: $0.58 (1.74%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$32.95
Buy:$32.96
Change: $0.58 (1.74%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Contact details

Address:
100 Fifth Avenue
WALTHAM
02451
United States
Telephone:
+1 (617) 9775700
Website:
https://apellis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APLS
ISIN:
US03753U1060
Market cap:
$4.14 billion
Shares in issue:
124.39 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Cedric Francois
    President, Chief Executive Officer, Co-Founder, Director
  • Pascal Deschatelets
    Co-Founder, Chief Scientific Officer
  • Timothy Sullivan
    Chief Financial Officer, Treasurer
  • Nur Nicholson
    Chief Technical Operations Officer
  • Adam Townsend
    Chief Operating Officer
  • Karen Lewis
    Chief People Officer
  • James Chopas
    Chief Accounting Officer, Vice President, Corporate Controller
  • David Watson
    General Counsel
  • Caroline Baumal
    Chief Medical Officer
  • Mark Delong
    Chief Business and Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.